Beta Bionics Faces Class Action Over Alleged iLet Device Misrepresentations

The complaint centers on claims that Beta Bionics executives downplayed the severity of an FDA Form 483 received in October 2025. While leadership publicly characterized the agency's concerns as minor procedural issues regarding complaint reporting, the lawsuit alleges the FDA had actually identified critical malfunctions. Specifically, the device reportedly caused hypoglycemic events by delivering dangerously high insulin doses, with thousands of incidents requiring medical intervention.

The discrepancy between corporate assurances and regulatory findings came to a head on February 24, 2026, when the FDA publicly released a warning letter detailing systemic failures at the company. Following the disclosure, Beta Bionics stock plummeted from a January 2026 price of $31.99 to $12.89 by February 25. Investors seeking to serve as lead plaintiff in the case must contact Robbins LLP by November 3, 2026.